Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Assets (2023 - 2026)

Prelude Therapeutics' Non-Current Assets history spans 4 years, with the latest figure at $35.0 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 9.8% to $35.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $145.1 million, a 9.79% decrease, with the full-year FY2025 number at $35.6 million, down 10.09% from a year prior.
  • Non-Current Assets hit $35.0 million in Q1 2026 for Prelude Therapeutics, down from $35.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PRLD hit a ceiling of $42.1 million in Q4 2023 and a floor of $35.0 million in Q1 2026.
  • Historically, Non-Current Assets has averaged $39.0 million across 4 years, with a median of $39.2 million in 2024.
  • Biggest five-year swings in Non-Current Assets: fell 5.84% in 2024 and later decreased 10.8% in 2025.
  • Tracing PRLD's Non-Current Assets over 4 years: stood at $42.1 million in 2023, then decreased by 5.84% to $39.6 million in 2024, then fell by 10.09% to $35.6 million in 2025, then fell by 1.61% to $35.0 million in 2026.
  • Business Quant data shows Non-Current Assets for PRLD at $35.0 million in Q1 2026, $35.6 million in Q4 2025, and $36.4 million in Q3 2025.